ELRIG UK, a leading organization in the drug discovery community, has partnered with The Protein Society (TPS) to host a groundbreaking conference on ‘Protein Sciences in Drug Discovery’.
SpliceBio, a genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has partnered with Spark Therapeutics to develop a gene therapy for an inherited retinal disease.
Mission Bio has launched a tool it claims will help save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six months faster.
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems.
Teva Pharmaceuticals Australia has selected Berkeley Lights’ biological workflow platform to develop therapeutic antibodies at its R&D site in New South Wales.
Filtration drove a record quarter for Repligen which says the addition of Spectrum Pharmaceuticals will further grow its bioprocessing portfolio and geographical presence.
Regulators have granted CureVac a European patent for its mRNA vaccine and anti-PD-1 antibody technology designed to prevent and treat cancers and infectious diseases.
Takeda has teamed up with GammaDelta Therapeutics to develop novel T-cell-based therapies in a deal that includes an option to buy the year-old UK biotech.
A second single-use production line could offer commercial-scale capacity for bispecific antibodies but Glenmark says it would need to scale-up further to support more traditional biologics.
A two-step manufacturing process makes antibody-drug conjugate production expensive and causes stability issues, says Eleven Biotherapeutics which is fusing antibody fragments to cytotoxic proteins.
Shark antibodies are an attractive way to deliver biologics to the brain, says Ossianix which is using its blood-brain barrier (BBB) crossing technology in collaboration with Lundbeck.
Amgen will manufacture, trial and sell cancer immunotherapies developed in collaboration with Immatics Biotechnologies GmbH under an agreement announced this week.
Absorption Systems has announced a technology licensing agreement with Pfizer Inc., in which the pharma company will use the preclinical CRO’s cell lines to test potential drug candidates.
Sanofi, Merck & Co. and downstream technology firm Natrix have teamed to develop a chromatography system with a productivity level capable to enable a fully-integrated downstream platform.
WuXi Biologics will make a recombinant soluble LAG-3 protein on behalf of Prima Biomed from its 28,000L single-use facility in China set to open next year.
The US FDA has cleared Adaptimmune to start a trial of its fat cancer cell therapy, lifting the clinical hold imposed in August when the agency asked for more manufacturing data.
Sartorius Stedim Biotech (SSB) claims benchtop vaccine and protein purification techs could save developers €2000 per batch and reduce processing time by 60%.
Innova Biosciences says its AbPure Protein A-based system removes the need to undergo an additional step when purifying antibody in preparation for conjugation
Adaptimmune Therapeutics has entered a five-year manufacturing deal with PCT for its SPEAR T-cell pipeline ahead of the opening of its own facility in Philadelphia.
Germany's Merck says gene editing can make CHO cells resistant to a tiny mouse virus that continues to be a problem for even animal component-free production processes.
The US FDA has ordered Adaptimmune to halt a trial of its candidate liposarcoma therapy and asked for more information about how the treatment is made.
ProteoNic Biotechnology has licensed a vector gene delivery system to Horizon Discovery in a deal it hopes will attract firms looking to eliminate methionine sulphoximine from CHO cell selection processes.
Triazamacrocyclic lipid complexes increase the efficiency of antibody-drug conjugates (ADCs) by delivering the payload right into the heart of a cancer cell, says BioCellChallenge.
Microbial expression systems are cheaper and more efficient than mammalian cell cultures says BioSilta which has acquired the rights to an E. coli based platform.
The combination of Gyros and Protein Technologies will give biomanufacturers greater access to protein and peptide processing tools and reagents, the CEO says.
Protein A is essential in keeping the costs and complexity of purifying monoclonal antibodies down, says GE Healthcare as it extends its supply agreement with Repligen.
The Cell Therapy Catapult (CTC) UK is in talks over gene and cell therapy partnerships similar to its latest deal with Cancer Research Technology and the University of Birmingham, says Chief Business Officer Matthew Durdy.
Protea Biosciences has teamed up with Agilent Technologies to offer drugmakers mass spectrometry alternatives to UV detection in QA/QC of recombinant proteins.
Pfizer and Bioatla have licensed each other’s technology platforms to develop ADCs with Conditionally Active Biologic (CAB) antibodies as the payload delivery vehicles.
